Bjork Elisabeth sold $2.0M of PHVS
Bjork Elisabeth sold 52,500 shares of Pharvaris N.V. (PHVS) at $37.89 ($1.99M total) on 2026-09-17.
How this was made
The 30-second read
Why it matters
The director's sale reduces insider ownership, possibly affecting investor confidence.
Market read
Routine insider sale with modest size; limited trading impact.
What to watch
Potential upcoming clinical data could offset negative perception.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Bjork Elisabeth sold 52,500 shares for $1.99M, reducing her stake to 15,167 shares.
Potential short-term pressure on PHVS, limited to a few percent.
Form 4 filing is primary source; sale amount is notable but not material enough to drive large price move.
Market effects
May raise concerns for biotech sector insiders but limited impact.
No broader regional effect.
Minimal global relevance.
Counterpoint
Insider may be diversifying; sale does not reflect company fundamentals.
Key entities
- CompanyPharvaris N.V.
Biotech company listed on Nasdaq under ticker PHVS.
- IndividualBjork Elisabeth
Director of Pharvaris N.V. who sold shares.
